ARTICLE | Company News
Indevus licenses ATLC compound
July 1, 2002 7:00 AM UTC
IDEV received an exclusive worldwide license from Atlantic Technology Ventures (ATLC) to CT-3 anti-inflammatory and analgesic compound. CT-3 is a synthetic derivative of tetrahydrocannabinol (THC) tha...